Welcome to our dedicated page for Geovax Labs news (Ticker: GOVX), a resource for investors and traders seeking the latest updates and insights on Geovax Labs stock.
GeoVax Labs, Inc. (GOVX) is a clinical-stage biotechnology company whose news flow centers on vaccines for infectious diseases and therapies for solid tumor cancers. Company press releases describe active clinical development of GEO-CM04S1, a next-generation COVID-19 vaccine, and Gedeptin®, a gene-directed oncolytic therapy for head and neck cancers, along with additional programs such as the GEO-MVA Mpox/Smallpox vaccine candidate and MVA-VLP-based cancer immunotherapies.
Investors following GEO-CM04S1 news will see updates on Phase 2 trials in immunocompromised patients, chronic lymphocytic leukemia (CLL) patients, and healthy adults, as well as progress on a BARDA-funded 10,000-participant Phase 2b trial comparing GEO-CM04S1 with an approved COVID-19 vaccine. News items also cover interim data reviews, such as immune response outcomes in CLL booster studies, and broader context on the role of dual-antigen MVA-based vaccines in populations with limited responses to existing vaccines.
Oncology-related news highlights Gedeptin’s completed multicenter Phase 1/2 trial in advanced head and neck cancers and plans for a Phase 2 trial in first recurrent head and neck cancer in combination with an immune checkpoint inhibitor. Additional releases discuss preclinical data and intellectual property developments for candidates like MVA-VLP-MUC1, as well as participation in conferences and panel discussions on innovative therapies for solid tumors.
GeoVax news also includes corporate and financial updates, such as registered direct offerings and private placements of common stock and warrants, government contract revenues tied to the BARDA/Project NextGen award, and quarterly financial results. For investors and observers, the GOVX news stream provides insight into clinical milestones, regulatory and funding developments, patent allowances, and corporate presentations. Bookmarking this page allows readers to monitor how GeoVax’s vaccine and immuno-oncology programs progress through clinical stages and financing events over time.
GeoVax Labs, Inc. (GOVX) is set to present at the Maxim Group’s Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. The company’s Chairman and CEO, David Dodd, will discuss ongoing research in COVID-19 and cancer immunotherapy. Additionally, Mark Newman, PhD, Chief Scientific Officer, will join a panel on cancer vaccines and immuno-oncology. Investors can register for the conference to view presentations and schedule one-on-one meetings with Dodd.
GeoVax Labs announces the filing of two key patent applications focused on vaccines for SARS-CoV-2 and cancer immunotherapies. The International Patent Application under the Patent Cooperation Treaty aims to protect their COVID-19 vaccines, which target multiple viral antigens, potentially reducing susceptibility to mutations. Additionally, a U.S. patent application was filed to enhance immune responses to cancer through its modified vaccinia Ankara viral vector technology. The company now has over 70 patent applications and is advancing towards clinical development in both areas.
GeoVax Labs, Inc. (NasdaqCM: GOVX) will participate in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. Chairman and CEO David Dodd is set to present, with an on-demand listening option starting at 7:00 AM ET on March 9. The presentation will be available for 90 days. Investors can schedule virtual one-on-one meetings with Mr. Dodd during the conference. GeoVax is focused on developing vaccines for infectious diseases and cancer, including COVID-19 and HIV, utilizing an innovative vaccine platform.
GeoVax Labs, Inc. (NasdaqCM: GOVX) announced that CEO David Dodd and CFO Mark Reynolds will deliver a presentation titled “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” at a Tribe Public webinar on March 3, 2021, at 8:30 AM Pacific/11:30 AM Eastern. The event aims to engage audiences regarding their innovative vaccine technologies against infectious diseases and cancer. Interested participants can register for the complimentary ZOOM webinar.
GeoVax Labs, Inc. (GOVX) announced the successful closing of a bought deal offering, selling 1,644,000 shares at $6.25 each, resulting in gross proceeds of approximately $10.3 million. The offering included 204,000 shares from an underwriter's full exercise of additional shares option. Maxim Group LLC acted as the sole book-running manager for the offering. This initiative was conducted under a registration statement filed with the SEC. GeoVax is focused on developing vaccines for various infectious diseases and cancer, utilizing its patented MVA-VLP platform.
GeoVax Labs, Inc. (Nasdaq: GOVX) announced an underwriting agreement with Maxim Group LLC to sell 1,440,000 shares of common stock at $6.25 per share, aiming for gross proceeds of approximately $9.0 million before expenses. The underwriters also have an option to purchase an additional 204,000 shares. The offering is expected to close on February 11, 2021, pending customary conditions. Shares are being offered under a shelf registration statement previously approved by the SEC.
GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) has closed its public offering, raising $12.8 million by issuing 2,560,000 units of common stock, pre-funded warrants, and warrants. Each unit consists of one share of common stock and a five-year warrant at an exercise price of $5.00. The offering included 2,310,000 units priced at $5.00 per unit and 250,000 units at $4.99. The company granted underwriters a 45-day option for an additional 384,000 shares to cover over-allotments.
GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) announced a public offering of 2,560,000 units priced at $5.00 each, expected to yield $12.8 million before expenses. The offering includes common stock and warrants, starting trading on September 25, 2020. Concurrently, a 1-for-20 reverse stock split will take effect. The closing is anticipated on September 29, 2020, pending customary conditions. An additional 384,000 units may be purchased by underwriters within 45 days to cover over-allotments.